Frank Waldron-Lynch

Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.

B. Mulcahy, Frank Waldron-Lynch, Michael McDermott et al. · PubMed · 1996 · 174 citations

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

Kevan C. Herold, Stephen E. Gitelman, Steven M. Willi et al. · Diabetologia · 2012 · 153 citations

Type 1, Diabetes Management, Teplizumab Treatment +8

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

John A. Todd, Marina Evangelou, Antony J. Cutler et al. · PLoS Medicine · 2016 · 133 citations · Full text

Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients

Frank Waldron-Lynch, Octavian Henegariu, Songyan Deng et al. · Science Translational Medicine · 2012 · 88 citations · Full text

Tumour necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families

Frank Waldron-Lynch, Claire Adams, Christopher I. Amos et al. · Genes and Immunity · 2001 · 83 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14